NCT02954172View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC

PHASE3CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

November 28, 2016

Primary Completion Date

October 19, 2018

Study Completion Date

November 12, 2019

Conditions
NSCLC
Interventions
DRUG

Bevacizumab in Combination With Paclitaxel/Carboplatin

Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg

DRUG

IBI305 in Combination with Paclitaxel/Carboplatin

Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg

Trial Locations (1)

510060

Cancer Center; Sun Yat sen University;, Guangzhou

All Listed Sponsors
collaborator

WuXi CDS Clinical Research (Shanghai) Co.Ltd.

INDUSTRY

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT02954172 - Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC | Biotech Hunter | Biotech Hunter